Clinical trial · Observational
Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa
NCT01448187CI-TRIAL-00022825EPIDAUREcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- The Overall survival
- timeFrame
- 24 months
- measure
- The progression free survival
- timeFrame
- 24 months
Secondary outcomes (6)
- measure
- Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC)
- timeFrame
- baseline
- measure
- Description of Quality of life by Functional Assessment of Cancer Therapy - Lung including Life Stressor Checklist (FACT-L including LSC)
- timeFrame
- From baseline to 3 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 130 Years
Show eligibility criteria text
Inclusion Criteria: * Patients treated with Iressa Exclusion Criteria: * Patient included in a therapeutic trial comprising protocol use of Iressa * Patient included in a therapeutic trial (Huriet-Serusclat Act) * Patient refusing to participate in the study
References
Publications (0)
Data not yet available
No reference posted for this study.